Sneak Preview: Clinical Trial Policies Top IP As Biggest Obstacle To Indian Innovation
This article was originally published in PharmAsia News
Executive Summary
Despite recent news flow focused on a challenging patent environment, India’s pharma market is expected to grow 13% annually to reach $45 billion by 2020, according to a McKinsey report to be released June 21 during the annual U.S.-India BioPharma & Healthcare Summit in Boston.
You may also be interested in...
Ranbaxy's Anti-Malarial Approval Makes It First Indian Firm To Fully Develop An NCE
MUMBAI - For Ranbaxy Laboratories Ltd., it has been nearly a decade-long bumpy ride to discover and develop its anti-malarial compound, but India's regulator - the Drug Controller General of India - finally granted the company a conditional approval to market the compound
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.
China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports